Rheumatoid Arthritis Market Size in the 7MM was ~USD 31,000 Million in 2025, it is expected to grow at a CAGR of 2% during 2026–2036

The Rheumatoid Arthritis (RA) market size across the seven major markets (7MM: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan) was approximately USD 31,000 million in 2025 and is projected to grow at a CAGR of 2% during 2026–2036. The public DelveInsight page does not disclose the exact 2036 market value.

Rheumatoid Arthritis is a chronic systemic inflammatory autoimmune disease characterized primarily by persistent inflammation of the joints. It typically presents as bilateral, symmetric polyarthritis involving the hands and feet, although other synovial joints and extra-articular organs, including the skin, heart, lungs, and eyes, can also be affected.

The disease is believed to arise from a combination of genetic predisposition and environmental triggers such as smoking or infection. Persistent inflammation can result in progressive joint destruction, disability, reduced quality of life, and systemic complications. Early diagnosis and appropriate treatment are therefore essential to suppress inflammation, achieve remission, prevent structural damage, and preserve function.

The RA treatment landscape has evolved substantially with the introduction of conventional DMARDs, biologic DMARDs, and targeted synthetic DMARDs. Methotrexate remains a key first-line therapy, while biologics and JAK inhibitors are used in patients with inadequate response or intolerance to conventional treatment.

Rheumatoid Arthritis Market Growth Drivers

Key factors expected to drive the Rheumatoid Arthritis market include:

• Rising global disease burden: RA is a chronic autoimmune disease associated with persistent inflammation, pain, disability, and reduced quality of life.

• Growing patient population: Increasing prevalence and aging populations are contributing to a larger disease burden.

• Improved diagnosis: Greater disease awareness and advances in diagnostic evaluation are supporting earlier identification.

• Targeted treatment approaches: Biologic DMARDs and targeted synthetic DMARDs are expanding treatment options.

• Increasing use of JAK inhibitors: Oral targeted therapies have broadened the treatment paradigm for patients inadequately responding to conventional or biologic therapies.

• Treat-to-target strategies: Early and aggressive treatment aimed at remission or low disease activity is improving disease management.

• Pipeline innovation: Emerging therapies targeting novel inflammatory and immune pathways are expected to create additional market opportunities.

Rheumatoid Arthritis Market and Epidemiology Insights

Rheumatoid Arthritis represents a substantial clinical and socioeconomic burden. In the United States, approximately 1.3 million adults are estimated to suffer from RA, representing approximately 0.6%–1% of the adult population.

In the United Kingdom, the estimated prevalence of RA among adults is approximately 0.81%, with a substantially higher prevalence among women (1.16%) than men (0.44%).

According to the World Health Organization data cited by DelveInsight, approximately 70% of people living with RA are women, while approximately 55% are older than 55 years.

First-degree relatives of individuals with RA have an estimated 2–3-fold increased risk of developing the disease. The relatively low concordance among monozygotic twins, approximately 15%–20%, highlights the important contribution of environmental factors to disease development.

Major Companies and Therapies in the Rheumatoid Arthritis Market

Leading companies involved in the Rheumatoid Arthritis treatment market include Rise Therapeutics, Taiho Pharmaceutical, AbbVie, Eli Lilly and Company/Incyte, AstraZeneca, and others.

Key marketed and emerging therapies include:

• Upadacitinib (RINVOQ) – AbbVie

• Baricitinib (OLUMIANT) – Eli Lilly and Company/Incyte

• CIMZIA (certolizumab pegol)

• R-2487 – Rise Therapeutics

• TAS5315 – Taiho Pharmaceutical

• AZD1163 – AstraZeneca

• AZD6912 – AstraZeneca

• NTM-001

• Ocadusertib – Eli Lilly and Company

• MYMD-1 – TNF Pharmaceuticals.

Rheumatoid Arthritis Market Geography

DelveInsight's Rheumatoid Arthritis market analysis covers the 7MM, comprising:

• North America: United States

• Europe: Germany, France, Italy, Spain, and the United Kingdom

• Asia-Pacific: Japan.

The report evaluates country-specific epidemiology, treatment practices, market size, therapy uptake, reimbursement, competitive dynamics, and emerging opportunities across all seven markets.

Rheumatoid Arthritis Market Report Description

DelveInsight's “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2036” provides an in-depth assessment of the Rheumatoid Arthritis disease landscape, epidemiology, current treatment practices, emerging therapies, competitive landscape, market trends, and future market outlook across the United States, EU4, the United Kingdom, and Japan.

The report covers the 2022–2036 study period, including 2022–2025 as the historical period and 2026–2036 as the forecast period. It evaluates patient burden, market size, therapy-level market share, drug uptake, treatment addressable market, unmet needs, pricing, reimbursement, and competitive dynamics.

To know in detail about the Rheumatoid Arthritis market, request a sample of the report.

Some of the Key Facts of the Rheumatoid Arthritis Market Report

• The 7MM Rheumatoid Arthritis market was approximately USD 31,000 million in 2025.

• The market is projected to grow at approximately 2% CAGR during 2026–2036.

• Approximately 1.3 million adults in the US are estimated to have RA.

• US adult RA prevalence is estimated at approximately 0.6%–1%.

• UK adult RA prevalence is approximately 0.81%.

• Women account for approximately 70% of people living with RA.

• Approximately 55% of people with RA are older than 55 years.

• First-degree relatives of people with RA have a 2–3-fold increased risk.

• Approximately 15%–20% monozygotic twin concordance highlights the role of non-genetic factors.

• Targeted therapy utilization in Japan has been reported to range from approximately 18% to 50%.

• Major companies include Rise Therapeutics, Taiho Pharmaceutical, AbbVie, Eli Lilly and Company/Incyte, and AstraZeneca.

• Key therapies include upadacitinib, baricitinib, CIMZIA, R-2487, and TAS5315.

Rheumatoid Arthritis Overview

Rheumatoid Arthritis is a chronic systemic autoimmune disease of unknown cause. It primarily affects the synovial joints and commonly presents with bilateral, symmetric polyarthritis involving the hands and feet. However, the disease can also affect the knees, shoulders, elbows, ankles, and other joints, as well as extra-articular organs.

RA is thought to develop in genetically predisposed individuals following exposure to environmental triggers. Genetic factors such as HLA-DR4/DR1 carriage, together with environmental factors including smoking and infection, may contribute to initiation of the autoimmune response.

Persistent inflammation can cause cartilage destruction, bone erosion, joint deformity, functional impairment, and systemic complications. RA therefore requires long-term disease management rather than short-term symptomatic treatment.

Rheumatoid Arthritis Diagnosis

No single diagnostic test definitively establishes RA. Diagnosis is based on clinical evaluation supported by laboratory and imaging findings.

Important diagnostic assessments include:

• Erythrocyte sedimentation rate (ESR)

• C-reactive protein (CRP)

• Rheumatoid factor (RF)

• Anti-cyclic citrullinated peptide (anti-CCP) antibodies

• X-ray

• Ultrasound

• Magnetic resonance imaging (MRI).

Imaging helps identify structural joint damage and assess disease progression, while inflammatory markers and autoantibodies provide additional evidence supporting diagnosis and disease monitoring.

Current Rheumatoid Arthritis Treatment Landscape

The primary objectives of RA treatment are to suppress inflammation, achieve remission or low disease activity, relieve symptoms, prevent structural joint damage, and improve long-term physical function.

Disease-modifying antirheumatic drugs (DMARDs) represent the foundation of treatment. Methotrexate remains a key first-line DMARD because of its efficacy, relatively rapid onset, tolerability, and cost-effectiveness.

For patients who do not achieve treatment goals, therapy may be optimized or escalated to biologic or targeted synthetic DMARDs.

Biologic therapies include:

• TNF-α inhibitors, including HUMIRA, CIMZIA, and SIMPONI

• IL-6 pathway inhibitors, including ACTEMRA and KEVZARA

• T-cell costimulation modulators

• B-cell depletion therapies.

Targeted synthetic DMARDs, particularly JAK inhibitors such as XELJANZ, upadacitinib, and baricitinib, have expanded treatment options for patients who do not respond adequately to conventional or biologic therapies.

Supportive management includes exercise, physiotherapy, occupational therapy, lifestyle modification, and patient engagement. Surgery is generally reserved for advanced or refractory disease.

Get a comprehensive understanding of the Rheumatoid Arthritis market, epidemiology, patient burden, current treatment landscape, emerging therapies, competitive environment, market trends, and future opportunities through DelveInsight's market research report.

Request the free sample to explore the complete Rheumatoid Arthritis market analysis.

Key Trends in Rheumatoid Arthritis Therapeutics Market

The RA therapeutic landscape has shifted from conventional symptomatic treatment toward early, aggressive, treat-to-target disease management.

DMARDs remain central to treatment, while biologic and targeted synthetic DMARDs are increasingly used to achieve disease control in patients with inadequate responses to conventional treatment. JAK inhibitors have further expanded treatment choices by providing effective oral targeted therapy.

The emerging pipeline is increasingly focused on novel immune and inflammatory pathways. BTK inhibition, regulatory T-cell modulation, and other targeted mechanisms could potentially address treatment-resistant disease and improve outcomes for patients who fail existing therapies.

Rheumatoid Arthritis Epidemiology

According to DelveInsight's epidemiological analysis:

• Approximately 1.3 million US adults suffer from RA.

• US adult prevalence is approximately 0.6%–1%.

• UK adult prevalence is approximately 0.81%.

• Women account for approximately 70% of people living with RA.

• Approximately 55% of people with RA are older than 55 years.

• Women in the UK have an estimated prevalence of 1.16%, compared with 0.44% in men.

• Targeted therapy utilization in Japan ranges from approximately 18% to 50%.

• Global age-standardized RA prevalence has increased over recent decades, while mortality has declined.

• The hands, wrists, feet, ankles, knees, shoulders, and elbows are among the joints most frequently affected.

Rheumatoid Arthritis Epidemiology Segmentation

The Rheumatoid Arthritis epidemiology is segmented into:

• Total prevalent cases

• Total diagnosed prevalent cases

• Gender-specific cases

• Age-specific cases

• Severity-specific cases

• Patients receiving targeted therapies

• Line-wise treated cases.

Recent Developments in the Rheumatoid Arthritis Treatment Landscape

• January 2025: Rise Therapeutics announced completion of dose-escalation enrollment for both R-2487 and R-3750 clinical trials. Both programs were expected to proceed to planned dose-expansion stages.

• According to AstraZeneca's FY clinical trial appendix 2025, AZD1163 advanced to Phase II, while AZD6912 remained in Phase I. Data for both programs are anticipated after 2026.

Rheumatoid Arthritis Drug Uptake and Pipeline

The RA pipeline contains therapies designed to address inflammation and immune dysregulation through mechanisms beyond conventional DMARDs.

TAS5315 – Taiho Pharmaceutical

TAS5315 is a novel, highly selective Bruton’s tyrosine kinase (BTK) inhibitor. BTK inhibition may help regulate inflammatory processes and bone erosion by affecting immune effector cells including B cells, macrophages, and osteoclasts.

Taiho Pharmaceutical is evaluating TAS5315 in a Phase II trial in combination with methotrexate in patients with RA who have demonstrated inadequate response to methotrexate in Japan.

R-2487 – Rise Therapeutics

R-2487 is an orally administered targeted immunotherapy designed to induce regulatory T cells and restore immune balance in autoimmune diseases such as RA.

The therapy is intended to activate specific immune pathways and reduce inflammatory cytokines involved in autoimmune pathology. R-2487 is currently in Phase I development.

AZD1163 – AstraZeneca

AZD1163 is an emerging AstraZeneca therapy being evaluated for RA. According to the company's 2025 clinical trial appendix cited by DelveInsight, the program has advanced to Phase II, with data expected after 2026.

AZD6912 – AstraZeneca

AZD6912 is another emerging AstraZeneca candidate being investigated in RA. The program remains in Phase I, according to the 2025 clinical trial appendix cited by DelveInsight.

Key Approved Rheumatoid Arthritis Therapies

Upadacitinib (RINVOQ) – AbbVie

Upadacitinib is a JAK inhibitor indicated for adults with moderate-to-severe RA who have experienced inadequate response or intolerance to methotrexate.

It modulates signaling through the JAK pathway, preventing phosphorylation and activation of STAT proteins. Upadacitinib received regulatory approval in the US and European Union in 2019, followed by approval in Japan in 2020.

Baricitinib (OLUMIANT) – Eli Lilly and Company/Incyte

Baricitinib is an oral JAK inhibitor indicated for adults with moderately to severely active RA who have had an inadequate response to one or more TNF antagonist therapies.

It received approval in the European Union and Japan in 2017, followed by US approval in 2018.

Rheumatoid Arthritis Market Outlook

The RA market is expected to grow modestly through 2036, with the 7MM market increasing from approximately USD 31 billion in 2025 at a 2% CAGR during 2026–2036.

The market's evolution is expected to be driven by continued use of conventional DMARDs, increasing adoption of biologic and targeted synthetic DMARDs, and the introduction of therapies with novel mechanisms of action.

Treat-to-target management, early aggressive intervention, and individualized treatment selection are expected to remain central to future disease management.

Rheumatoid Arthritis Market Drivers

Key market drivers include:

• Rising global RA burden

• Increasing aging population

• Improved diagnosis and disease awareness

• Increasing adoption of treat-to-target strategies

• Continued use of DMARDs

• Growing utilization of biologic DMARDs

• Expansion of JAK inhibitor therapies

• Increasing research into novel immune pathways

• Greater focus on remission and low disease activity

• Development of personalized therapeutic strategies

• Increasing investment in RA drug development.

Rheumatoid Arthritis Market Barriers

Major barriers affecting the RA market include:

• Inadequate treatment response

• Lack of predictive biomarkers

• Safety and tolerability concerns

• Delayed diagnosis

• Disease heterogeneity

• Long-term treatment requirements

• Treatment adherence challenges

• High cost of certain biologic and targeted therapies

• Access and reimbursement limitations

• Need for continuous monitoring and treatment adjustment.

Rheumatoid Arthritis Market Access and Reimbursement

Reimbursement is an important factor affecting access to RA therapies. DelveInsight evaluates country-specific accessibility, reimbursement scenarios, cost-effectiveness, affordability programs, insurance coverage, and out-of-pocket costs across the 7MM.

In the United States, reimbursement and access programs identified by DelveInsight include Olumiant Together and the Lilly Cares Foundation for baricitinib.

The report also evaluates how therapy pricing relative to clinical benefit can influence market access, adherence, and long-term uptake.

Rheumatoid Arthritis Industry Expert and KOL Insights

DelveInsight's analysts connected with 15+ KOLs across the 7MM to gather country-level insights regarding emerging therapies, treatment practices, patient adherence, therapy switching, drug adoption and uptake, accessibility challenges, epidemiology, and real-world prescribing patterns.

Experts from institutions including Harvard Medical School, the University of Oxford, the University of California, San Francisco, and the University of Heidelberg contributed perspectives to the analysis.

KOL insights help assess current and emerging treatment approaches, unmet medical needs, market access, therapy adoption, and pipeline prioritization.

Scope of the Rheumatoid Arthritis Market Report

The DelveInsight Rheumatoid Arthritis market report provides comprehensive coverage of:

• Historical and forecasted market analysis from 2022–2036

• Epidemiology across the 7MM

• Total prevalent cases

• Diagnosed prevalent cases

• Gender-specific cases

• Age-specific cases

• Severity-specific cases

• Patients receiving targeted therapies

• Line-wise treated cases

• Current treatment practices

• Treatment algorithms

• Approved therapies

• Emerging therapies

• Clinical development analysis

• Drug uptake

• Therapy-level market share

• Competitive landscape

• Market drivers and barriers

• Unmet medical needs

• Treatment addressable market

• Pricing and analogue assessment

• Market access and reimbursement

• KOL insights

• Patient journey

• Treatment preferences

• SWOT analysis

• Conjoint analysis

• Market attractiveness

• Peak patient share analysis.

The report covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, providing an 11-year forecast and an epidemiology-based bottom-up assessment of the Rheumatoid Arthritis therapeutics market.

To learn more about the Rheumatoid Arthritis market, treatment landscape, emerging therapies, competitive environment, and forecast through 2036, request the detailed report from DelveInsight.

About DelveInsight

DelveInsight is a life sciences and healthcare market research and consulting company providing market intelligence, epidemiology analysis, pipeline assessment, competitive landscape evaluation, market forecasting, and consulting solutions.

The DelveInsight Rheumatoid Arthritis report integrates epidemiological analysis, treatment-landscape assessment, competitive intelligence, market forecasting, drug uptake analysis, pricing and reimbursement assessment, KOL insights, SWOT and conjoint analysis, and evaluation of unmet medical needs to provide a comprehensive view of the Rheumatoid Arthritis market across the 7MM.